摘要
目的试图通过对DNA免疫的方法进行改进达到增强免疫效率及改变免疫应答类型。方法应用丙型肝炎病毒(HCV)结构区基因重组体(PC和PCE1E2)与白细胞介素(IL)-12p35和p40编码基因重组体(PIL-12),转染真核细胞并对其表达产物进行检测,并且将pC、pCE1E2与pIL-12联合免疫BALB/C鼠,对其体液免疫和体内、体外细胞免疫应答进行检测。结果所构建的重组体均可在真核细胞内瞬时或稳定表达特异性抗原蛋白。PC和PCE1E2与PIL-12共免疫时可引起BALB/C鼠脾肿大和脾细胞数增多,HCV抗原特异性CTL反应增强,单独PC和PCE1E2免疫鼠的CTL活力,pC为(18.65±5.71)%,pCE1E2(20、07±11.11)%,PC+pIL-12为(60.11±17.37)%,pCE1E2+pIL-12为(67.48±15.57)%。但联合pIL-12免疫后抗HCV反应减低,免疫后8周平均A值:PC为0.415±0.127,pCE1E2为0.358±0.096,PC+PIL-12为0.210±0.086,PCE1E2+pIL-12为0.258±0.125。结论与IL-12共免疫可增强DNA?
Objective In an attempt to demonstrate the utility of DNA vaccines for the tailoredmethods, the efficacy of immune responses would be enhanced and the types of immune responses shifted.Methods Four recombinant plasmids were constructEd. These included the HCV coding regions for thecore protein(pC) and for the core E1 and E2 together(pCE1E2) IL-12 p35 and p40. These plasmids weretransfected into mammalian cells to test their protein expression and were injected into the quadricepsmuscles of BALB/C mice to measure specific antibodies and cytotoxic T-lymphocyte responses. Rll the recombinant plasmids were shown to express specific antigens in cells transiently and stably.Codelivery of pIL-12 expression cassettes with pC and pCE1E2 in mice resulted in splenomegaly and theincreasing number of the splenocytes. It also resulted in the enhancement of Ag-dependent CTL responses andthe reduction of specific Ab response. The CTL activity were pC=18.65% 5.71%, PCEIE2=20.07% 11.ll%,pC+p1L-12=60. 11% 17.37%, pCE1E2+pIL-12=67.48% 15.57%, respectively. The Anti-HCV activity werepC=0.415 0. 127, pCE1E2=0.358 0.096, pC+pIL-12=0.210 0.086, pCE1E2+pIL-12=0.258 0.125, respetively.Conclusion Codelivery of pIL-12 with plasmid DNA can enhance the efficacy of immune responses andshift the type of immune responses. This work demonstrates the power of DNA delivery in vivo for boththe production of a new g6neration of more effective and targeted vaccines or immuno-therapies as wellas an analytic tool for the molecular dissection of the mechanisms of immune function.
出处
《中华肝脏病杂志》
CAS
CSCD
1999年第4期236-239,共4页
Chinese Journal of Hepatology
基金
国家和浙江省自然科学基金